Nandrolone Decanoate injection 250 mg
Each 1ml contains:
Nandrolone Decanoate 250 mg
Deca 250is an injectable anabolic preparation. After injection, Nandrolone Decanoate is gradually released from the intramuscular depot and subsequently hydrolysed into nandrolone.
As an anabolic steroid.
Certain cases of disseminated breast cancer in women.
Osteoporosis due to androgen deficiency in hypogonadal males.
Not intended for use in children.
Known or suspected prostatic carcinoma and mammary carcinoma in the male.
Not intended for use in female patients other than those with disseminated breast cancer.
Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal failure, hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular and hepatic carcinoma.
DOSAGE AND DIRECTIONS FOR USE
Deca250 should be administered by deep intramuscular injection.
Adult dose: Usual dose of 25 mg to 50 mg per ml every three weeks. Can be given 100 to 200 mg every 3 weeks.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS
Virilisation which appears in sensitive women as hoarseness, acne, hirsutism, and increased libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice.
Other adverse reactions may include:
-Oligospermia and decreased ejaculatory volume;
-Suppression of ovarian activity, atrophy of the breasts and endometrial tissue.
-Amenorrhoea and inhibition of spermatogenesis.
-Water and salt retention.
-Premature epiphyseal closure.
-If signs of virilisation develop, treatment should be discontinued.
-Increase in nitrogen retention and skeletal weight;
-Increased vascularity of the skin;
-Increased growth of the bone;
-Elderly males may become over-stimulated.
Patients with the following conditions should be monitored:
latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may induce salt and fluid retention;
diabetes, since anabolic steroids may improve the glucose tolerance and decrease the need for insulin or other antidiabetic dugs;
ncomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure;
skeletal metastases, since anabolic steroids may induce hypercalcaemia and hypercalciuria in these patients.
Liver-enzyme-inducing agents may reduce the effects of Deca250 by enhancing its metabolism in the liver.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
See “Side-effects and special precautions”. Treatment is symptomatic and supportive.
Store at room temperature below 30° C.